ICON plc
ICON is a contract research organization (CRO) which provides outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. These solutions span the clinical development lifecycle from compound selection to Phase I-III clinical studies and post approval outcome research and market access consulting solutions. ICON’s services assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster and the company has the expertise and capability to conduct clinical trials in most major therapeutic areas either on a stand-alone basis or as part of an integrated “full service” solution. ICON employs approximately 15,000 employees from 99 locations in 40 countries.
Contact details
Company details
- Phase I-IV Clinical Trial Design, Management and Review
- Clinical Pharmacology
- Global Central Laboratory and Bioanalytical Laboratory services
- Medical Imaging
- Contract Resourcing
- Product Development Planning;
- Strategic Consulting;
- Study Protocol Preparation;
- Clinical Pharmacology;
- Pharmacokinetic and Pharmacodynamic analysis;
- Clinical Research Centers;
- Investigator Sites;
- Patient Recruitment;
- Study Monitoring and Data Collection;
- Case Report Form ("CRF") Preparation;
- Statistical Analysis;
- Patient Safety Monitoring;
- Risk-based Monitoring;
- Clinical Data Management;
- Strategic Analysis and Data Operations;
- Regulatory Consulting;
- Medical Reporting and Pharmacovigilance;
- Interactive Response Technologies;
- Electronic Endpoint Adjudication;
- Medical Imaging;
- Adaptive trial design and execution;
- Medical Device Trials;
- Biosimilar Trials;
- Research Trials for US Government Agencies;
- Functional Services;
- Strategic Resourcing;
- Sample analyses;
- Safety testing;
- Microbiology;
- Custom flow cytometry;
- Electronic transmission of test results;
- Biomarker development;
- Bioanalysis;
- Immunoassay development;
- Electronic Patient Reported Outcomes;
- Patient Registries;
- Outcomes Research;
- Health Economics;
- Market Access and commercialization services;
- Drug Pricing Consulting; and
- Health care and scientific communications.
Latest content
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
Ardena announces €20m expansion following first GMP approval